Company intelligence / Profile preview

NanoSpot.ai

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

NanoSpot.ai has commercially launched a CE-marked SARS-CoV-2 Total Antibody Test that uses a rapid agglutination-based assay read by an AI-powered mobile application, providing semi-quantitative antibody results at the point of care with reported 97.6% sensitivity and 100% specificity in under 3 minutes.[2]

Therapeutic areas: HematologyCardiovascularInfectious Diseases
Modalities: DeviceNanoparticle
Industry: Protein Biomarker Diagnostics

Partnerships

Opto (an Athroa company) – commercialization of SARS-CoV-2 Total Antibody Test in Europe[2]University of Utah – technology origin and assay development for NanoSpot.AI platform[3]ARUP Laboratories – development and validation partner for NanoSpot.AI assay[3]Techcyte – AI-based image analysis platform for NanoSpot.AI diagnostics[3]

Beyond the preview

Go deeper on NanoSpot.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoSpot.ai.

Explore the full profile